COVID-19 vaccines and children

Dr. Manish Sadarangani

Director, Vaccine Evaluation Center, BC Children's Hospital Research Institute
Associate Professor, Division of Infectious Diseases, Department of Pediatrics, UBC
Physician Lead, Family Immunization Clinic, BC Children's Hospital

16 November, 2021







Disclosures

Salary awards

- BC Children's Hospital Foundation
- Michael Smith Foundation for Health Research
- Canadian Child Health Clinician Scientist Program

- Research/Project Funding
 - Merck, VBI Vaccines, GlaxoSmithKline, Pfizer, Sanofi-Pasteur, Seqirus, Symvivo


- All funds have been paid to my institute
- Not received any personal payments







BNT162b2 vaccine in 5-11yo children










BNT162b2 vaccine in 5-11yo children









BNT162b2 vaccine in 5-11yo children

	Dose/ Sampling Time Point ^a	Vaccine Group (as Randomized)											
Assay		BNT162b2						Placebo					
		10 μg 5 to <12 Years (C4591007)			30 μg 16-25 Years (C4591001)			5 to <12 Years (C4591007)			16-25 Years (C4591001)		
		n ^b	GMT ^c	(95% CI ^c)	n ^b	GMT°	(95% CI ^c)	n ^b	GMT ^c	(95% CI ^c)	n ^b	GMT ^c	(95% CI°)
SARS-CoV-2 neutralization assay - NT50 (titer)	1/Prevax	264	10.1	(9.9, 10.3)	253	10.3	(9.8, 10.8)	130	10.0	(10.0, 10.0)	45	10.0	(10.0, 10.0)
	2/1 Month	264	1197.6	(1106.1, 1296.6)	253	1146.5	(1045.5, 1257.2)	130	10.7	(9.7, 11.8)	45	10.0	(10.0, 10.0)





